Keyword Analysis & Research: thrombocytopenia ������

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
thrombocytopenia ������0.10.145067935
thrombocytopenia1.710.22402316
������1.270.356454718

Keyword Research: People who searched thrombocytopenia ������ also searched

Keyword CPC PCC Volume Score
thrombocytopenia ������0.640.5104855

Search Results related to thrombocytopenia ������ on Search Engine

  • Heparin-induced thrombocytopenia - American Society of …

    ashpublications.org

    https://ashpublications.org/blood/article/129/21/2864/36268/Heparin-induced-thrombocytopenia

    May 25, 2017 · Acute thrombocytopenia occurring within minutes of heparin therapy was first described in animals in 1942 7 and later observed in humans 8 as a transient, nonimmune complication of heparin therapy. This pharmacologic effect of heparin, referred to as type I HIT 9 is caused by the agglutinating effects of heparin on platelets. 10 The more serious, immune …

    DA: 14 PA: 25 MOZ Rank: 10

  • Platelet Disorders - Immune Thrombocytopenia (ITP) | NHLBI, NIH

    nih.gov

    https://www.nhlbi.nih.gov/health/immune-thrombocytopenia

    Mar 24, 2022 · Immune thrombocytopenia (ITP) is a type of platelet disorder. In ITP, your blood does not clot as it should, because you have a low platelet count. Platelets are tiny blood cells that are made in the bone marrow. When you are injured, platelets stick together to form a plug that seals your wound. This plug is called a blood clot.

    DA: 87 PA: 57 MOZ Rank: 39

  • thrombocytopenia - UpToDate

    uptodate.com

    https://www.uptodate.com/contents/thrombocytopenia

    Thrombocytopenia may increase bleeding risk, but it does not protect against venous thromboembolism (VTE) or stroke. Thus, caring for patients with both thrombocytopenia and an indication for anticoagulation ...

    DA: 58 PA: 10 MOZ Rank: 16

  • Thrombocytopenia (Low Platelet Count) - eMedicineHealth

    emedicinehealth.com

    https://www.emedicinehealth.com/thrombocytopenia_low_platelet_count/article_em.htm

    Oct 19, 2021 · The outlook for thrombocytopenia mainly depends on its cause and its severity. Only in very severe thrombocytopenia (platelet counts of less than 10,000 - 20,000), there may be a risk of spontaneous bleeding. Many cases of thrombocytopenia may be reversible (medication-induced, infectious), thus carrying a favorable prognosis.

    DA: 20 PA: 35 MOZ Rank: 37

  • Managing thrombocytopenia associated with cancer chemotherapy

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/25952492/

    Thrombocytopenia is a common problem in cancer patients. Aside from bleeding risk, thrombocytopenia limits chemotherapy dose and frequency. In evaluating thrombocytopenic cancer patients, it is important to assess for other causes of thrombocytopenia, including immune thrombocytopenia, coagulopathy, infection, drug reaction, post-transfusion purpura, …

    DA: 18 PA: 37 MOZ Rank: 31

  • National Center for Biotechnology Information

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2784425/

    National Center for Biotechnology Information

    DA: 6 PA: 71 MOZ Rank: 80

  • National Center for Biotechnology Information

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600013/

    National Center for Biotechnology Information

    DA: 54 PA: 2 MOZ Rank: 64

  • Thrombocytopenia platelet count range: Severe, moderate, and …

    medicalnewstoday.com

    https://www.medicalnewstoday.com/articles/thrombocytopenia-range

    Jan 14, 2022 · Thrombocytopenia ranges from mild, involving a platelet count of 101,000–140,000 per μl of blood, to very severe, where a person has a platelet count of 20,000 per μl or lower. Severe cases of ...

    DA: 11 PA: 70 MOZ Rank: 68

  • Immature platelet fraction: A useful marker for identifying the …

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/32049816/

    These data demonstrated that the IPF and delta AIPC are both excellent indicators of the etiology of thrombocytopenia and predictive markers for platelet recovery. Medicine (Baltimore) . 2020 Feb;99(7):e19096. doi: 10.1097/MD.0000000000019096.

    DA: 75 PA: 84 MOZ Rank: 97

  • Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/35417637/

    Apr 14, 2022 · Background: Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase, may increase platelet counts in patients with immune thrombocytopenia by means of dual mechanisms of action: decreased macrophage (Fcγ receptor)-mediated platelet destruction and reduced production of pathogenic autoantibodies. Methods: In an international, adaptive, …

    DA: 42 PA: 73 MOZ Rank: 76